新闻
ADXS
--
0.00%
--
Prostate Specific Antigen Market Size 2021 Pointing to Capture Largest Market Growth and Share with Developed Economies,Competitive Landscape and Regional Forecast 2026| New Report by Market Reports World
Jan 11, 2021 (The Expresswire) -- Global “Prostate Specific Antigen Market” is an overview of the global market which provides with prime focus on factors...
The Express Wire · 5天前
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 2020/11/25 12:35
Mid-Afternoon Market Update: Dow Tops 30,000; Goldfield Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 1.45% to 30,020 while the NASDAQ rose 1.27% to 12,032. The S&P also rose, gaining 1.53% to 3,632.
Benzinga · 2020/11/24 19:30
Mid-Day Market Update: Crude Oil Jumps Over 4%; Dycom Industries Shares Plummet
Midway through trading Tuesday, the Dow traded up 1.34% to 29,988.10 while the NASDAQ rose 0.95% to 11,993.07. The S&P also rose, gaining 1.34% to 3,625.43.
Benzinga · 2020/11/24 17:04
Advaxis Prices 26,666,666 Share Common Stock Offering At $0.30/Share
PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS) (the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy
Benzinga · 2020/11/24 13:36
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 2020/11/24 13:12
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
finviz · 2020/11/09 12:01
Advaxis' ADXS-503 Demonstrates Pronounced, Sustained Tumor Control In Ongoing Phase 1/2 Lung Cancer Trial
Advaxis' ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial Disease control rate of 67% in first six evaluable patients who had progressed
Benzinga · 2020/10/26 12:01
Advaxis ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
finviz · 2020/10/26 12:00
Advaxis To Present Data From Ongoing ADXS-503 Phase 1/2 Clinical Trial At SITC 2020
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020 PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on
Benzinga · 2020/10/15 12:18
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
finviz · 2020/10/15 12:00
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
finviz · 2020/09/29 12:30
Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
finviz · 2020/09/24 12:00
Advaxis Q3 EPS $(0.09) Up From $(1.00) YoY
Advaxis (NASDAQ:ADXS) reported quarterly losses of $(0.09) per share. This is a 91 percent increase over losses of $(1.00) per share from the same period last year.
Benzinga · 2020/09/10 12:13
Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
finviz · 2020/09/10 12:00
Advaxis Announces Resignation of Chief Financial Officer
finviz · 2020/09/04 20:30
LD Micro - 360 Companies Set to Present this Week
finviz · 2020/08/31 21:00
Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference
finviz · 2020/08/27 12:00
LD Micro Announces Preliminary List of Presenters for the LD 500
finviz · 2020/08/05 13:00
Edited Transcript of ADXS earnings conference call or presentation 11-Jun-20 3:00pm GMT
finviz · 2020/08/04 01:31
微牛提供丰富的实时ADXS股票新闻,让你可以通过多个平台了解ADXS股票行情最新动态,这些免费的Advaxis新闻可以帮助你做出明智投资。
ADXS 简况
Advaxis, Inc.是一家致力于李斯特菌(Lm)- 李斯特菌溶血素(LLO)癌症免疫疗法的发现、开发和商业化的临床阶段生物技术公司。该公司的免疫疗法基于将活减毒Lm生物工程改造为分泌抗原/佐剂融合蛋白的平台技术。Lm-LLO菌株将多种功能整合到单一免疫治疗中,Lm-LLO菌株接触与指导抗原呈递细胞以刺激抗肿瘤T细胞的免疫,用多种佐剂等同物刺激与激活免疫系统,并同时减少 肿瘤微环境的癌症保护,使T细胞能够消除肿瘤。Axalimogene filolisbac是该公司治疗人类乳头病毒相关癌症的主导Lm-LLO免疫治疗候选产品。ADXS-PSA是该公司针对前列腺癌中前列腺特异性抗原(PSA)的Lm-LLO免疫治疗候选产品。
展开